VIR-2482 is a monoclonal antibody commercialized by Vir Biotechnology, with a leading Phase II program in Influenzavirus A Infections. According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, and 2 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of VIR-2482’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for VIR-2482 is expected to reach an annual total of $99 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
VIR-2482 is under development for the prevention of influenza A virus infection. It is administered via intramuscular route. The drug candidate is being developed based on Xencor’s XtendTM technology platform.
Vir Biotechnology Overview
Vir Biotechnology (Vir) is a biotechnology company which carries out the development of therapeutic products to prevent and treat serious infectious diseases. It develops treatments for viral and bacterial diseases and those that induce protective and therapeutic immune responses. The company undertakes a multi-program, multi-platform approach to apply these breakthroughs. Vir primarily focuses on chronic infectious diseases including hepatitis B, tuberculosis, and HIV; respiratory diseases, including influenza, respiratory syncytial virus (RSV), and metapneumovirus (MPV); and healthcare-acquired infections. It operates in Portland, Oregon, Boston, Massachusetts, Bellinzona, Switzerland. Vir is headquartered in San Francisco, California, the US.
The company reported revenues of (US Dollars) US$1,095.4 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$76.4 million in FY2020. The operating profit of the company was US$420.8 million in FY2021, compared to an operating loss of US$297 million in FY2020. The net profit of the company was US$528.6 million in FY2021, compared to a net loss of US$298.7 million in FY2020.
For a complete picture of VIR-2482’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.